logo
Losing weight in middle age could reduce chronic diseases later, study shows

Losing weight in middle age could reduce chronic diseases later, study shows

CNN27-05-2025
Sign up for CNN's Fitness, But Better newsletter series. Our seven-part guide will help you ease into a healthy routine, backed by experts.
All the work that goes into losing weight in middle age could set you up for a longer, healthier life later, according to a new study.
A sustained weight loss of about 6.5% of body weight without medications or surgery in middle-aged people is linked to substantial long-term health benefits, said lead study author Dr. Timo Strandberg, professor of geriatric medicine at the University of Helsinki in Finland.
Those benefits included a reduction of risk for both chronic diseases and death from all causes.
The study, published Tuesday in the journal JAMA Network Open, analyzed data of about 23,000 people from three different groups across different time periods: one group from 1985 to 1988, another from 1964 to 1973, and a third between 2000 and 2013.
Researchers grouped the people in the studies based on their starting body mass index (BMI) and whether they gained, lost or maintained weight and compared the patterns with hospitalizations and death records.
People who lost weight in midlife were less likely to experience heart attacks, strokes, cancer, asthma or chronic obstructive pulmonary disease in their older years, according to the study.
Those who lost weight were also less likely to have died of any cause over the next 35 years, the study found.
It's important to note that much of the data was collected before weight loss medications or surgeries were widely available, meaning that the benefits largely came from body changes driven by alterations in diet and exercise, Strandberg said.
The study is important because it provides evidence of the relationship between weight loss and both cardiovascular disease and mortality, which hasn't been studied enough, said Dr. Aayush Visaria, a clinical researcher and incoming instructor of medicine at Rutgers Robert Wood Johnson Medical School in New Jersey. He was not involved in the research.
Although the study is strong in that it utilizes a large sample, there are some limitations when applying the results, Visaria said.
The study was conducted on White Europeans, meaning that it's difficult to generalize the results to different populations, Strandberg said.
'BMI is very different across different racial ethnic groups,' Visaria said.
And BMI, which looks at weight in proportion to height, isn't always the most accurate way to gauge body composition, he added. BMI is still used widely because it is easy to calculate, but it doesn't differentiate based on a person's proportion of bone or muscle, Visaria said.
'There's so many variables that might play into how someone's body composition changes, even though maybe their weight might not change as much,' Visaria said.
Other studies suggest that the fat distribution makes a big difference –– the fat around a person's organs may be what really drives a lot of disease risk, he said.
Lifestyle changes –– such as a healthy diet and more exercise –– were important factors in the risk reduction.
The study was observational, meaning that the data can show a relationship between weight loss and a reduction in chronic disease and mortality risk, but researchers can't say for sure that the weight loss was the factor that lowered the risk, Visaria said.
Although the researchers adjusted for other factors that could influence the risk, such as age, they did not adjust for lifestyle behaviors such as diet and physical activity, he added. Those changes could be behind the lowered risk of chronic diseases just as the weight loss itself could be, Visaria said.
Both weight loss and the behavioral changes behind it are often tied together in improving health, Strandberg noted.
Weight loss relieves conditions such as osteoarthritis, obstructive sleep apnea and fatty liver, while changes to diet and exercise have been shown to decrease cardiovascular risks, he added.
Lifestyle is always important when it comes to good health, meaning that you should continue to strive for a healthy diet and good physical activity –– even if you are using weight loss medications, Visaria said.
The Mediterranean diet –– which prioritizes fruits, vegetables, grains, olive oil, and nuts and seeds –– has consistently been ranked the best diet for wellness and disease prevention.
Studies suggest this way of eating may improve bone density in older years, prevent some cancers and lower risk of heart disease.
For physical activity, the World Health Organization recommends that adults engage in at least 150 minutes per week of moderate-intensity or 75 minutes of vigorous-intensity aerobic activity, along with muscle-strengthening activities at least twice a week.
However, obesity is not just a problem individuals need to tackle –– it is a structural issue as well, Strandberg said.
Healthy foods and opportunities for physical activity need to be more accessible in modern societies to help curb the health impacts associated with obesity, he added.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Maziar Mike Doustdar appointed as president and chief executive officer of Novo Nordisk
Maziar Mike Doustdar appointed as president and chief executive officer of Novo Nordisk

Yahoo

timean hour ago

  • Yahoo

Maziar Mike Doustdar appointed as president and chief executive officer of Novo Nordisk

Bagsværd, Denmark, 29 July 2025 – Novo Nordisk today announced that Maziar Mike Doustdar has been appointed as president and chief executive officer, effective 7 August 2025. Mike Doustdar succeeds Lars Fruergaard Jørgensen, who will step down as president and chief executive officer on the same date. The company also announced other executive-level changes, effective 7 August. Mike Doustdar, currently Novo Nordisk's executive vice president of International Operations, has a strong track record of creating value and driving growth. Under his leadership over the past decade, Novo Nordisk's International Operations have more than doubled sales to approximately DKK 112 billion in 2024. The business includes all of Novo Nordisk's affiliates outside of the US and employs nearly 20,000 people. Novo Nordisk Chair, Helge Lund, said: 'Mike is an exceptional leader and has the unanimous support of the Board. We are confident that he is the best person to lead Novo Nordisk through its next growth phase. Mike has consistently demonstrated the ability to drive growth through strong commercial execution and building high-performing teams. This is an important moment for Novo Nordisk. The market is developing rapidly, and the company needs to address recent market challenges with speed and ambition. I believe Novo Nordisk will build on its strengths as a global leader in obesity and diabetes, and Mike has a clear vision of how to unlock the full potential of the opportunities ahead.' Mike Doustdar has been appointed as the result of a comprehensive process that included external and internal candidates. The Novo Nordisk Foundation fully endorses Novo Nordisk Board's decision to appoint Maziar Mike Doustdar as president and chief executive officer. Mike Doustdar said: 'It's an enormous privilege to lead this company at a time of tremendous opportunity and change. I come to this role with a sense of urgency, a laser focus on high performance, and a fierce determination for Novo Nordisk to aim higher than it's ever done, and to deliver to many more patients the innovation they need. From my decades in leadership roles across Novo Nordisk, I know the extraordinary talent and commitment of our people and the excellence of our science. This has enabled us to achieve great things in the past and will ensure we continue to do so in the future.' Novo Nordisk Chair, Helge Lund, added: 'Under Lars's leadership, Novo Nordisk has undergone a profound period of growth and now reaches millions more patients with life-changing medicines. On behalf of Novo Nordisk's Board of Directors and our employees, I want to thank Lars for 34 years of unstinting commitment to the company and wish him all the best in his future endeavours.' Other organisational changes effective 7 August: Research & Early Development and Development EVP areas will be merged into a combined R&D Nordisk has decided to merge the company's Research & Early Development with its Development area into a new, consolidated R&D unit, under the leadership of Martin Holst Lange, MD, PhD. Martin Holst Lange, currently executive vice president, Development, will be appointed chief scientific officer (CSO), effective 7 August. Martin Holst Lange will focus on seamlessly combining the two functions, quickly advancing the innovation of new therapies and ensuring the success of the early and late-stage pipelines, with a significant focus on the diabetes and obesity areas. In addition, Martin Holst Lange will work closely with Mike Doustdar to drive pipeline development and innovation from both within and outside of the company. Marcus Schindler, executive vice president, Research & Early Development and CSO, has decided to retire from the company. Novo Nordisk Chair, Helge Lund, said: 'We thank Marcus for his deep commitment to Novo Nordisk and its pursuit of scientific excellence. We wish him all the best for the future.' Marcus Schindler joined Novo Nordisk in January 2018 as senior vice president of External Innovation and Strategy and has been CSO since 2021. Marcus Schindler has played an integral role in leading the discovery of early scientific innovation. He will remain at Novo Nordisk for a short period to ensure a successful transition. Emil Kongshøj Larsen, currently senior vice president of the Europe and Canada region (EUCAN), will join Executive Management and succeed Mike Doustdar, assuming the responsibility of executive vice president, International Operations. Emil Larsen currently leads a region spanning 40 countries, accounting for about 20% of Novo Nordisk's global sales. He has previously led other significant business areas throughout Europe, Africa and the Middle East, as well as Commercial Affairs and Strategy in International Operations. With these changes, Executive Management will have the following members, effective 7 August: Maziar Mike Doustdar, president and CEO* Thilde Hummel Bøgebjerg, EVP, Quality, IT & Environmental Affairs Emil Kongshøj Larsen, EVP, International Operations Ludovic Helfgott, EVP, Product & Portfolio Strategy Karsten Munk Knudsen, EVP, chief financial officer* Martin Holst Lange, EVP, chief scientific officer, Research & Development David Moore, EVP, US Operations Tania Sabroe, EVP, People, Organisation and Corporate Affairs Henrik Wulff, EVP, CMC & Product Supply * Registered as an executive with the Danish Business Authority. About Maziar Mike DoustdarMike Doustdar became senior vice president of International Operations in 2013, a business that includes 80 affiliates - all of Novo Nordisk's commercial affiliates outside of the US. Novo Nordisk's International Operations had sales of approximately DKK 112 billion in 2024 and serve approximately 35 million patients. Prior to this role, Mike led Novo Nordisk's Southeast Asia and Oceania commercial area out of Malaysia, following on from his leadership of the Middle East business. Prior to this, he was general manager based in Turkey and held leadership roles in finance and IT. Mike Doustdar became executive vice president in 2015. He is a member of the Board of Directors of Orion Corporation. Conference CallNovo Nordisk will host a conference call for investors at 14.30 CEST on 29 July 2025, corresponding to 8.30 am EST. For more information on how to listen, please visit the investor section of There will be a conference call for media at 16.00 CEST, which corresponds to 10.00 am EST. Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit Facebook, Instagram, X, LinkedIn and YouTube. Contacts for further information Media: Ambre James-Brown +45 3079 9289abmo@ Liz Skrbkova (US)+1 609 917 0632lzsk@ Investors: Jacob Martin Wiborg Rode+45 3075 5956jrde@ Sina Meyer +45 3079 6656azey@ Max Ung+45 3077 6414 mxun@ Frederik Taylor Pitter +1 609 613 0568fptr@ Publication of inside information pursuant to Market Abuse Regulation, Article 17 Company announcement No 19 / 2025 Attachment CA250729-CEO-succession

🚨 Ter Stegen undergoes successful surgery, return date still unknown
🚨 Ter Stegen undergoes successful surgery, return date still unknown

Yahoo

timean hour ago

  • Yahoo

🚨 Ter Stegen undergoes successful surgery, return date still unknown

The operation of Marc André Ter Stegen has been confirmed. The FC Barcelona goalkeeper underwent surgery this Tuesday to address his lumbar issues. "The first team player Marc Ter Stegen has successfully undergone surgery again for his lumbar problems by Dr. Amélie Léglise, under the supervision of the Club's Medical Services, at the Sports Clinic Bordeaux Merignac. He is out and his recovery will determine his availability", reads the Barça statement. The club has not provided information regarding his recovery time. This has sparked a debate focusing on the situation of the Barça goalkeeping position. The difficulties in registering Joan García have prompted discussions on how many months Ter Stegen will be sidelined. This article was translated into English by Artificial Intelligence. You can read the original version in 🇪🇸 here. 📸 Alex Grimm - 2025 Getty Images

Spire Global Awarded European Space Agency Contract for Weather Data
Spire Global Awarded European Space Agency Contract for Weather Data

Yahoo

timean hour ago

  • Yahoo

Spire Global Awarded European Space Agency Contract for Weather Data

LUXEMBOURG, July 29, 2025--(BUSINESS WIRE)--Spire Global, Inc. (NYSE: SPIR) ("Spire" or "the Company"), a global provider of space-based data, analytics and space services, was awarded a contract by the European Space Agency (ESA) under the Third Party Mission (TPM) programme to supply historical weather data collected by its satellites. Under the programme, European researchers will have access to Spire's historical Earth intelligence data, including GNSS-Reflectometry and Polarimetric Radio Occultation data, to support cutting-edge science and the development of operational applications. These datasets provide insight on sea ice, soil moisture and precipitation, amongst other climate variables. "The TPM programme supports Spire in delivering novel Earth observation products to the Earth science community in Europe," said Matthieu Talpe, a Remote Sensing Product Engineer at Spire. "Our datasets are already shaping the future of climate research, enabling breakthroughs like enhanced weather forecasts at ECMWF, the world's premier weather forecasting institution. We can't wait to see how researchers leverage this data to address global challenges." "Through our Third Party Mission programme, we aim to empower Europe's scientific community with access to high-impact commercial Earth observation data," said Peggy Fischer, Third Party Missions Manager at the European Space Agency. "We're proud to work with Spire to make its GNSS-Reflectometry and Polarimetric Radio Occultation data available to the European scientific community, helping advance both research and pre-operational Earth observation capabilities across the continent." About Spire Global, Inc. Spire (NYSE: SPIR) is a global provider of space-based data, analytics and space services, offering unique datasets and powerful insights about Earth so that organizations can make decisions with confidence in a rapidly changing world. Spire builds, owns, and operates a fully deployed satellite constellation that observes the Earth in real time using radio frequency technology. The data acquired by Spire's satellites provides global weather intelligence, ship and plane movements, and spoofing and jamming detection to better predict how their patterns impact economies, global security, business operations and the environment. Spire also offers Space as a Service solutions that empower customers to leverage its established infrastructure to put their business in space. Spire has offices across the U.S., Canada, UK, Luxembourg, Germany and Singapore. To learn more, visit View source version on Contacts For media:Sarah FreemanSenior Communications For investors:Benjamin HackmanHead of Investor Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store